The evolution of treatment strategies: Aiming at the target

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 10-16

  Dinh, Phuong ^a   Sotiriou, Christos ^a   Piccart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Gene signatures; Stem cell; Target; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CD18 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS LIGAND; FLUOROURACIL; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; LAMININ; LAPATINIB; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; PROTEIN P53; SOMATOMEDIN; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; MICROMETASTASIS; MONOTHERAPY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 35649021683     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.032     Document Type: Article

References (60)

1. Gelber R.D., et al. Tailoring adjuvant treatments for the individual breast cancer patient. The Breast 12 (2003) 558-568
2. Eifel P., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 13 (2001) 979-989
3. Goldhirsh A., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16 10 (2005) 1569-1583
4. Jordan V.C., and Dowse L.J. Tamoxifen as an anti-tumor agent: effect on oestrogen binding. J Endocrinol 68 (1976) 297-303
5. Buzdar A.U., and Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 4 (1998) 527-534
6. Ravdin P.M., et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwestern Oncology Group study. J Clin Oncol 10 (1992) 1284-1291
7. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 265 (2005) 1687-1717
8. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 94 (2002) 1054-1065
9. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15 (1997) 1385-1394
10. Fisher B., Jeong J.-H., Bryant, et al. Treatment of lymph-node negative, estrogen-receptor-positive breast cancer: long term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 364 (2004) 858-868
11. Berry D.A., et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB and US Breast Intergroup. Proc. SABCS. 88 1 (2004) (Abstract 29)
12. Buzdar A.U., et al. Pathological complete response to chemotherapy is related to hormone receptor status. Proc SABCS 82 1 (2003) Abstract 302
13. Slamon D.J., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
14. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
15. Piccart-Gebhart M.J., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
16. Romond E.H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
17. Slamon D., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 suppl 1 (2005) S5 Abstract 1
18. Joensuu H., et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer trial. Breast Cancer Res Treat 94 Suppl 1 (2005) Abstract 2
19. C. Kim, et al., Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and c-MYC suggests pro-apoptotic function of dysregulated c-MYC in vivo, San Antonio Breast Cancer Symposium 2005; Abstract 46.
20. Nagata Y., et al. PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
21. Fujita T., et al. PTEN activity could be a predictive marker for trastuzumab in the treatment of erbB2-overexpressing breast cancer. Br J Cancer 94 2 (2006) 247-252
22. Molina M.A., et al. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61 12 (2001) 4744-4749
23. Perou C.M., et al. Molecular portraits of human breast tumors. Nature 406 (2000) 747-752
24. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98 (2001) 10869-10874
25. Carey L.A., et al. Race and the poor prognosis basal-like breast cancer (BBC) phenotype in the population-based Carolina Breast Cancer Study. J. Clin. Oncol. suppl (2004) (abstract 9510)
26. R. Rouzier, et al., Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium. San Antonio, TX 2004; abstract 1026.
27. van't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
28. van de Vijver M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. Nature 347 25 (2002) 1999-2009
29. Wang Y., et al. Gene-expression profiles to predict distant metastases of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
30. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98 17 (2006) 1183-1192
31. C. Desmedt, et al., Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Late breaking abstract, Fifth European Breast Cancer Conference, 2006.
32. Paik S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
33. Sotiriou C., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98 4 (2006) 262-272
34. Chang H.Y., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2 2 (2004) E7
35. Miller L.D., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 102 (2005) 13550-13555
36. Liu R., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356 (2007) 217-226
37. Loi S., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25 (2007) 1239-1246
38. Fan C., et al. Concordance among gene-expression-based predictors for breast cancer. N. Eng. J. Med. 355 (2006) 560-569
39. Sotiriou C., et al. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstr 507)
40. Jansen M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Info. 23 (2005) 732-740
41. Ma X.J., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 (2004) 607-616
42. Ma X.J., et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol. 24 (2006) 4611-4619
43. Jansen M.P., et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J. Clin. Oncol. 25 (2007) 662-668
44. Folgueira M.A., et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 11 (2005) 7434-7443
45. Hannemann J., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 23 (2005) 3331-3342
46. Chang J.C., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
47. Chang J.C., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23 (2005) 1169-1177
48. Iwao-Koizumi K., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23 (2005) 422-431
49. Bertucci F., et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 64 (2004) 8558-8565
50. Andre F., et al. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. Biochim. Biophys. Acta. 1766 (2006) 197-204
51. Rouzier R., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 8315-8320
52. Gianni L., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23 (2005) 7265-7277
53. Hess K.R., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24 (2006) 4236-4244
54. Bild A., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
55. Potti A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12 (2006) 1294-1300
56. Desmedt C., et al. Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clin. Cancer Res. 13 11 (2007) 3207-3214
57. Schmidt-Kittler O., et al. From disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100 13 (2003) 7737-7742
58. Klein C.A., et al. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle Aug 5 16 (2006) 1788-1798 August 15, 2006
59. Braun S., et al. A pooled analysis of bone marrow micrometastases in breast cancer. N Engl J Med 353 (2005) 793-802
60. Xenidis N., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24 (2006) 3756-3762